A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 - AZD3293hADME

Study identifier:D5010C00007

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion After Oral Administration of [14C]-AZD3293 to Healthy Male Subjects

Medical condition

Healthy Volunteers, mass balance study

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3293

Sex

Male

Actual Enrollment

12

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 May 2014
Primary Completion Date: 01 May 2014
Study Completion Date: 01 May 2014

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research

Verification:

Verified 01 Jun 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria